Novogen Limited Stock Australian S.E.
Stocks
AU000000NRT0
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 225M 159M 137M 128M 117M 221M 15.14B 1.51B 591M 7.57B 596M 583M 25.22B | P/E 2026 * |
-18x | P/E 2027 * | -19.7x |
|---|---|---|---|---|---|
| Enterprise Value | 225M 159M 137M 128M 117M 221M 15.14B 1.51B 591M 7.57B 596M 583M 25.22B | EV / Sales 2026 * |
629x | EV / Sales 2027 * | 1,549x |
| Free-Float |
45.6% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -89.73% |
| Manager | Title | Age | Since |
|---|---|---|---|
John Friend
CEO | Chief Executive Officer | 56 | 2023-04-30 |
James Levine
DFI | Director of Finance/CFO | 55 | 2026-05-31 |
Sudha Rao
CTO | Chief Tech/Sci/R&D Officer | - | 2026-04-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Steven Coffey
BRD | Director/Board Member | 65 | 2012-11-05 |
John Friend
CHM | Chairman | 56 | 2023-08-10 |
Ebru Davidson
BRD | Director/Board Member | - | 2023-06-04 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -89.73% | -7.32% | - | - | 159M | |
| +1.29% | +3.09% | +6.43% | +18.53% | 49.47B | |
| +0.89% | +12.90% | +493.60% | +590.98% | 43.97B | |
| +3.08% | +14.00% | +23.45% | +80.73% | 39.6B | |
| +1.38% | +3.32% | +33.88% | +8.71% | 39.29B | |
| +0.85% | +7.66% | +21.22% | +48.78% | 32.43B | |
| +0.08% | +4.30% | - | - | 16.84B | |
| +1.99% | +3.96% | +32.51% | +122.68% | 16.49B | |
| +0.34% | +2.76% | +5.39% | +20.43% | 14.01B | |
| +3.56% | +16.87% | +81.17% | +23.99% | 12.77B | |
| Average | -8.22% | +7.72% | +87.21% | +114.35% | 29.43B | |
| Weighted average by Cap. | +0.98% | +7.93% | +107.32% | +139.66% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 357K 252K 218K 204K 187K 352K 24.06M 2.39M 939K 12.03M 947K 926K 40.08M | 145K 102K 88.69K 82.9K 75.76K 143K 9.77M 972K 381K 4.89M 385K 376K 16.28M |
| Net income | -25.84M -18.25M -15.8M -14.77M -13.5M -25.44M -1.74B -173M -67.96M -871M -68.54M -67.05M -2.9B | -30.37M -21.45M -18.57M -17.36M -15.87M -29.9M -2.05B -204M -79.88M -1.02B -80.56M -78.8M -3.41B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
